drugset
drugset / Trial / NCT01049399

Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy

NCT01049399 ↗

Completed 146 enrolled Noscira SA i3 Research · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine wether NP031112 is safe and effective in the treatment of mild to moderate Progressive Supranuclear Palsy

Timeline

Start
2009-12
Primary completion
2011-09
Completion
2011-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tideglusib Small molecule 600 mg Oral
Subject Tideglusib Small molecule 800 mg Oral

Indications

progressive supranuclear palsy